Veterinärmedizinische Universität Wien Forschungsinformationssystem VetDoc

Grafischer Link zur Startseite der Vetmeduni Vienna

Gewählte Publikation:

Publikationstyp: Zeitschriftenaufsatz
Dokumenttyp: Originalarbeit

Jahr: 2010

AutorInnen: Wolfesberger, B; Tonar, Z; Gerner, W; Skalicky, M; Heiduschka, G; Egerbacher, M; Thalhammer, JG; Walter, I

Titel: The tyrosine kinase inhibitor sorafenib decreases cell number and induces apoptosis in a canine osteosarcoma cell line.

Quelle: Res Vet Sci. 2010; 88(1):94-100

Autor/innen der Vetmeduni Vienna:

Egerbacher Monika
Gerner Wilhelm
Skalicky Monika
Thalhammer Johann
Walter Ingrid
Wolfesberger Birgitt

Beteiligte Vetmed-Organisationseinheiten
Institut für Physiologie, Pathophysiologie und Biophysik, Abteilung für Physiologie, Pathophysiologie und experimentelle Endokrinologie
Institut für Immunologie
Institut für Topographische Anatomie
Universitätsklinik für Kleintiere, Klinische Abteilung für Interne Medizin Kleintiere

Canine osteosarcoma, an aggressive cancer with early distant metastasis, shows still despite good chemotherapy protocols poor long term survival. The aim of our study was to determine whether sorafenib, a novel multikinase inhibitor, has any effect on D-17 canine osteosarcoma cells. A cell proliferation kit was used for detecting surviving cells after treatment for 72 h with sorafenib or carboplatin or their combination. A significant decrease of neoplastic cells was observed after incubation with 0.5-16 microM sorafenib or with 80-640 microM carboplatin. Using immunocytochemistry for activated caspase 3 to evaluate apoptosis, we found significantly more positive cells in the sorafenib treated groups. Paradoxically, expression of the nuclear proliferation marker Ki-67 was also significantly higher in sorafenib treated cells. The drug sorafenib showed potent antitumour activity against D-17 canine osteosarcoma cells in vitro, suggesting a potential as a therapeutic tool in the treatment of bone cancer in dogs.

Keywords Pubmed: Animals
Antineoplastic Agents/pharmacology
Antineoplastic Agents/therapeutic use*
Apoptosis/drug effects*
Benzenesulfonates/therapeutic use*
Bone Neoplasms/drug therapy
Bone Neoplasms/enzymology
Bone Neoplasms/veterinary*
Caspase 3/metabolism
Cell Count
Cell Line, Tumor
Dog Diseases/drug therapy*
Dog Diseases/enzymology
Flow Cytometry
Ki-67 Antigen/metabolism
Microscopy, Electron, Transmission
Niacinamide/analogs & derivatives
Osteosarcoma/drug therapy
Phenylurea Compounds
Protein-Tyrosine Kinases/antagonists & inhibitors*
Pyridines/therapeutic use*

© Veterinärmedizinische Universität Wien Hilfe und DownloadsErklärung zur Barrierefreiheit